(Q34416316)

2 August 2017

1 reference

title

Management of hepatitis C in HIV-infected persons (English)

1 reference

2 August 2017

1 reference

Rodríguez-Rosado R

1

1 reference

2 August 2017

Pérez-Olmeda M

series ordinal

2

1 reference

2 August 2017

García-Samaniego J

series ordinal

3

1 reference

2 August 2017

Soriano V

series ordinal

4

1 reference

2 August 2017

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

52

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

189-198

1 reference

Epidemiology of hepatitis C

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

1 reference

7 January 2021

Basic concepts in RNA virus evolution

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Which patients with hepatitis C develop liver complications?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: comparison of second- and third-generation anti-HCV testing

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Hepatitis C virus infection in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Hepatotoxicity after introduction of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Hepatitis C and HIV infection: biological, clinical, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Management of chronic hepatitis C in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

The progression of HCV-associated liver disease in a cohort of haemophilic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

Correlates of hepatitis C virus infections among injection drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2801%2900184-X

7 January 2021

10.1016/S0166-3542(01)00184-X

Identifiers

DOI

1 reference

2 August 2017

1 reference